1. Home
  2. About us

About Enodia Therapeutics

Rooted in pioneering research from the Institut Pasteur and built by Argobio, Enodia launched in 2025 to advance a differentiated approach to targeted protein degradation, initially focused on inflammatory and autoimmune diseases.

Our Vision
To build a selective targeted protein degradation platform to unlock previously undruggable secreted and membrane protein targets to treat high-unmet-need conditions.

Our Mission
To develop best-in-class small molecules, targeting the Sec61 translocon, to degrade single or multiple disease-related proteins at the point of synthesis, before they can exert pathological effects.

Our history

Scientific origin:

Originating from foundational research conducted at Institut Pasteur, led by Prof. Caroline Demangel.

Company creation:

Selected and incubated by Argobio Studio to develop a platform-based biotech.

Development:

Enodia Therapeutics established in 2025 to develop a differentiated targeted protein degradation approach leveraging the secretory pathway, with a focus on the Sec61 translocon.

Growth & ambition:

Supported by leading investors and scientists, with the ambition to advance best-in-class therapies in inflammation and auto-immune diseases.

Our values

Scientific rigor with an exploratory mindset.

We combine scientific rigor with disciplined exploration to unlock new therapeutic potential.

Focused execution with agility and resilience.

We pursue clear therapeutic objectives with focus, adapting rapidly as data and context evolve.

Integrity, respect and quality as non-negotiables.

We act with integrity, transparency, and uncompromising quality toward people, partners, and science.

The heart of Enodia

Contact us for more details
Team
Scientific Advisory Board
Yves Ribeil
Yves RIBEILL, Ph.D.
Chief Executive Officer
Read more
Helene ASNAGLI
Hélène ASNAGLI, Ph.D.
Scientific Director
Read more
Aurore HICK
Aurore HICK, Ph.D.
Head of Biochemistry
Read more
Morgane SCHWENZER
Morgane SCHWENZER
Chief of Staff
Read more
Caroline DEMANGEL
Caroline DEMANGEL, Ph.D. 
President of the Scientific Advisory Board & Co-Founder
Read more
Michaela MULLER-TRUTWIN
Michaela MULLER-TRUTWIN
Read more
Professor Stephen HIGH
Professor Stephen HIGH
Read more
Alan KORMAN
Alan KORMAN
Read more
Bernard MALISSEN
Bernard MALISSEN
Read more

Built by Argobio and supported by:

mission bio